Rui‐Hua Xu

Research interests

Publications

• Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00620-7

• Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-023-02465-7

• Gastric cancer treatment: recent progress and future perspectives

  Journal of Hematology & Oncology · 2023 · https://doi.org/10.1186/s13045-023-01451-3

• Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

  Cancer Cell · 2022 · https://doi.org/10.1016/j.ccell.2022.02.007

• Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

  JAMA · 2021 · 10.1001/jama.2021.12836

• Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020

  癌症：英文版 · 2021 · https://doi.org/10.1002/cac2.12197

• The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

  癌症：英文版 · 2021 · https://doi.org/10.1002/cac2.12193

• Circular RNA: metabolism, functions and interactions with proteins

  Molecular Cancer · 2020 · https://doi.org/10.1186/s12943-020-01286-3

• LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer

  癌症：英文版 · 2020 · https://doi.org/10.1002/cac2.12108

• N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis

  Nature Communications · 2019 · https://doi.org/10.1038/s41467-019-12651-2

• METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma

  Molecular Cancer · 2019 · https://doi.org/10.1186/s12943-019-1038-7

• The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

  癌症：英文版 · 2019 · https://doi.org/10.1186/s40880-019-0349-9

• Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?

  癌症：英文版 · 2019 · https://doi.org/10.1186/s40880-019-0368-6

• Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz197

• Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx738

• Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma

  Nature Materials · 2017 · https://doi.org/10.1038/nmat4997

• DNA methylation markers for diagnosis and prognosis of common cancers

  Proceedings of the National Academy of Sciences · 2017 · https://doi.org/10.1073/pnas.1703577114

• Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.63.5995

• Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)70156-7

• Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

  Gastric Cancer · 2014 · https://doi.org/10.1007/s10120-014-0351-5

• Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2 -Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

  Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2013.53.6136

• Glycolysis inhibition for anticancer treatment

  Oncogene · 2006 · https://doi.org/10.1038/sj.onc.1209597

• Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia

  Cancer Research · 2005 · https://doi.org/10.1158/0008-5472.613.65.2

Current projects

No projects listed.